| SOXS 1.79 4.07% | NVDA 177.19 -4.16% | ONMD 1.02 44.60% | NFLX 96.24 13.77% | JEM 0.096 3.90% | ENSC 0.6232 57.77% | BYND 0.9456 15.32% | PLUG 1.79 -6.28% | SOFI 17.76 -7.02% | NVD 7.53 8.50% | TZA 6.23 5.06% | NU 14.98 -0.53% | DUST 3.54 -3.50% | BITO 9.06 -2.78% | EOSE 5.695 -15.50% | XLF 51.43 -2.04% | BAC 49.83 -4.72% | AAL 13.07 -6.24% | MARA 8.94 5.80% | VEEA 0.5071 17.33% | SPY 685.99 -0.48% | SOXL 62.77 -3.93% | SLV 84.99 5.64% | XWEL 1.49 9.56% | QQQ 607.29 -0.32% | ONDS 10.08 -3.54% | BHAT 0.0495 -11.13% | PSKY 13.51 20.84% | INTC 45.61 0.33% | F 14.095 -2.19% | AAPL 264.18 -3.21% | XLE 55.92 1.58% | TQQQ 49.52 -1.06% | TSLA 402.51 -1.49% | HYG 80.72 -0.16% | TSDD 9.18 2.91% | TSLL 14.7 -3.10% | BATL 5.52 33.01% | RKT 18.19 2.36% | RXT 1.95 -14.47% | TLT 90.82 0.61% | TSLS 5.64 1.62% | WBD 28.17 -2.19% | PATH 10.73 0.14% | CRWV 79.56 -18.51% | IBIT 37.19 -2.80% | LQD 111.68 -0.04% | SOUN 8.6015 -4.21% | PLTR 137.19 0.92% | CPNG 19.08 1.98%

Azenta, Inc. (NASDAQ: AZTA) Overview: A Leader in Life Sciences Solutions

Azenta, Inc. (NASDAQ: AZTA) is a prominent figure in the life sciences sector, specializing in sample exploration and management solutions. The company, formerly known as Brooks Automation, Inc., underwent a rebranding in December 2021 to better reflect its focused vision and services. Azenta operates through two main segments: Life Sciences Products and Life Sciences Services, catering to a diverse clientele including pharmaceutical and biotechnology companies, biorepositories, and research institutes.

The financial outlook for Azenta remains positive, with a stable consensus price target of $38 over recent months. However, Evercore ISI projects a more optimistic future for the company, setting a price target of $62. This optimism is supported by Azenta's strong financial performance, highlighted by a 36% increase in third-quarter earnings per share (EPS). With the fiscal fourth quarter and full year 2025 earnings report on the horizon, investors and analysts alike are keen to see if Azenta can maintain its growth trajectory.

Key Insights:

- Azenta, Inc. operates in the life sciences industry, offering automated cold sample management systems and comprehensive sample management programs.

- The consensus price target for Azenta has remained stable at $38, with Evercore ISI setting a more optimistic target of $62.

- Azenta reported a 36% increase in third-quarter EPS, indicating strong operational performance and supporting the higher price target set by Evercore ISI.

Azenta's upcoming fiscal fourth quarter and full year 2025 earnings report, scheduled for November 21, 2025, is eagerly anticipated. This report will offer further clarity on the company's financial health and its potential for future growth. With key figures like President and CEO John Marotta and CFO Lawrence Lin leading the charge, Azenta is well-positioned to continue its trajectory in the life sciences sector. The consistent price target set by analysts, particularly the bullish outlook from Evercore ISI, underscores the confidence in Azenta's strategic direction and operational success.

Published on: November 20, 2025